Fasedienol for phobia, social

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 15 Feb 2021: Trial registered, NCT04754802
  2. 24 May 2021: Trial started, NCT04754802
  3. 28 Mar 2024: Trial started, NCT06358651
  4. 10 Apr 2024: Trial registered, NCT06358651
  5. 16 Sep 2024: Trial started, NCT06615557
  6. 26 Sep 2024: Trial registered, NCT06615557

The trials

NCT02622958: Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

State
Completed
Phase
Phase 3
People
23 taking part
Started
Mar 2014
Primary completion
Oct 2014
Arms
PH94B Nasal Spray
Results
None posted
  1. 7 Dec 2015: Trial registered

NCT04754802: PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

State
Completed
Phase
Phase 3
People
224 taking part
Started
24 May 2021
Primary completion
22 Jun 2022
Arms
PH94B
Results
Posted on the registry
  1. 15 Feb 2021: Trial registered
  2. 24 May 2021: Trial started
  3. 22 Jun 2022: Trial completed
  4. 12 Sep 2025: Trial results posted

NCT05011396: PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

State
Stopped early
Phase
Phase 3
People
228 taking part
Started
30 Aug 2021
Primary completion
16 Aug 2022
Arms
PH94B
Results
Posted on the registry
  1. 18 Aug 2021: Trial registered
  2. 30 Aug 2021: Trial started
  3. 16 Aug 2022: Trial terminated
  4. 24 Nov 2025: Trial results posted

NCT05030350: Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

State
Stopped early
Phase
Phase 3
People
481 taking part
Started
1 Oct 2021
Primary completion
23 Sep 2022
Arms
PH94B 3.2 micrograms
Results
Posted on the registry
  1. 1 Sep 2021: Trial registered
  2. 1 Oct 2021: Trial started
  3. 23 Sep 2022: Trial terminated
  4. 21 Oct 2025: Trial results posted

NCT06358651: Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

State
Completed
Phase
Phase 3
People
238 taking part
Started
28 Mar 2024
Primary completion
31 Oct 2025
Arms
Fasedienol Nasal Spray
Results
None posted
  1. 28 Mar 2024: Trial started
  2. 10 Apr 2024: Trial registered
  3. 13 Jul 2026: Trial completed

NCT06615557: Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

State
Completed
Phase
Phase 3
People
238 taking part
Started
16 Sep 2024
Primary completion
21 Apr 2026
Arms
Fasedienol Nasal Spray
Results
None posted
  1. 16 Sep 2024: Trial started
  2. 26 Sep 2024: Trial registered
  3. 14 Jul 2026: Trial completed

NCT06809179: A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

State
Completed
Phase
Phase 2
People
61 taking part
Started
9 Jan 2025
Primary completion
12 Jun 2026
Arms
Fasedienol Nasal Spray (single dose), Fasedienol Nasal Spray (repeat dose)
Results
None posted
  1. 9 Jan 2025: Trial started
  2. 5 Feb 2025: Trial registered
  3. 26 Aug 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Fasedienol Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Fasedienol Nasal Spray - Placebo Nasal Spray, PH94B Nasal Spray.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.